2m 2m 2m 2m 2m 2m 2m
KYMERA THERAP (KYMR)
NASDAQ
$98.33-$1.12 (-1.13%)
Price as of Jun 23, 2026 4:10 PM EDT- $8.2BMarket Cap
- 114.84%1-Year Change
- BiotechnologyIndustry
KYMERA THERAP (KYMR)
$98.33-$1.12 (-1.13%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 39.2M -16.70% | 47.1M -40.11% | 78.6M +67.84% | 46.8M -35.71% | |
Cost of Revenue | 39.2M -16.70% | 47.1M N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 -100.00% | 78.6M +67.84% | 46.8M -35.71% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -316.6M +31.77% | -240.2M +27.06% | -189.1M +15.12% | -164.2M +19.87% | |
Depreciation and Amortization Expense | 8.3M +12.75% | 7.4M +106.82% | 3.6M +19.75% | 3.0M +24.20% | |
Total Operating Expenses | 388.6M +25.88% | 308.7M +26.46% | 244.1M +17.32% | 208.1M +20.03% | |
Operating Profit | -349.4M +33.54% | -261.6M +58.06% | -165.5M +2.65% | -161.3M +60.41% | |
Interest Income | 38.4M +1.03% | 38.0M +102.65% | 18.8M +183.27% | 6.6M +1,257.38% | |
Interest Expense | -4.2M -18.34% | -5.2M N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 34.2M +4.08% | 32.9M +75.08% | 18.8M +183.27% | 6.6M +1,257.38% | |
Total Nonoperating Income and Expense | 38.0M +0.72% | 37.8M +103.45% | 18.6M +187.97% | 6.4M +1,960.06% | |
Income before Taxes | -311.4M +39.08% | -223.9M +52.32% | -147.0M -5.07% | -154.8M +54.47% | |
Income Taxes | 0 N/A | N/A N/A | N/A N/A | 0 N/A | |
Extraordinary Items | N/A N/A | 4.9M N/A | N/A N/A | N/A N/A | |
Net Income | -311.4M +39.08% | -223.9M +52.32% | -147.0M -5.07% | -154.8M +54.47% | |
Net Income from Continuing Operations Applicable to Common | -311.4M +39.08% | -223.9M +52.32% | -147.0M -5.07% | -154.8M +54.47% | |
Basic EPS and Net Income | -3.69 +23.83% | -2.98 +18.25% | -2.52 -12.20% | -2.87 +37.32% | |
Diluted EPS and Net Income | -3.69 +23.83% | -2.98 +18.25% | -2.52 -12.20% | -2.87 +37.32% | |
Basic Weighted Average Shares | 84.5M +12.59% | 75.0M +28.58% | 58.4M +8.22% | 53.9M +12.39% | |
Diluted Weighted Average Shares | 84.5M +12.59% | 75.0M +28.58% | 58.4M +8.22% | 53.9M +12.39% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 357.0M +196.88% | 120.3M +9.36% | 110.0M +60.78% | 68.4M +42.56% | |
Short-Term Investments | 491.3M +33.32% | 368.5M +39.10% | 264.9M -21.80% | 338.8M -14.11% | |
Cash and Cash Equivalents and Short-Term Investments | 848.3M +73.56% | 488.7M +30.37% | 374.9M -7.93% | 407.2M -7.97% | |
Total Current Assets | 871.2M +70.74% | 510.3M +25.89% | 405.3M -3.36% | 419.4M -7.06% | |
Accumulated Depreciation | 22.1M +37.67% | 16.1M +53.96% | 10.4M +51.46% | 6.9M +76.02% | |
Property and Plant and Equipment and Net | 43.2M -14.43% | 50.5M +4.83% | 48.1M +260.99% | 13.3M +12.23% | |
Total Long-Term Assets | 9.1M +367.38% | 1.9M -7.93% | 2.1M -29.80% | 3.0M +49.21% | |
Total Assets | 1.7B +78.20% | 978.0M +69.87% | 575.8M -4.54% | 603.1M -0.46% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 83.2M +22.79% | 67.8M -20.92% | 85.7M +20.11% | 71.3M -22.91% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 78.5M N/A | 0 N/A | 0 -100.00% | 248,000 +275.76% | |
Total Liabilities | 163.1M +14.56% | 142.4M -21.22% | 180.8M +60.01% | 113.0M -22.76% | |
Retained Earnings | -1.1B +41.26% | -754.6M +42.18% | -530.8M +38.29% | -383.8M +67.61% | |
Total Stockholders Equity | 1.6B +89.04% | 835.6M +111.56% | 395.0M -19.42% | 490.2M +6.64% | |
Total Shares Outstanding | 81.3M +25.32% | 64.9M +16.74% | 55.6M +0.99% | 55.0M +6.80% | |
Cash Flow | |||||
Cash from Operating Activities | -232.9M +19.74% | -194.5M +89.16% | -102.8M -32.83% | -153.1M +18.72% | |
Capital Expenditures | 1.4M -88.71% | 12.8M -62.77% | 34.5M +1,115.80% | 2.8M +77.58% | |
Cash from Investing Activities | -521.1M +28.95% | -404.1M -388.86% | 139.9M +581.74% | 20.5M +120.55% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 990.7M +62.72% | 608.9M +14,424.12% | 4.2M -97.26% | 153.0M -38.87% | |
Financials Ratio | |||||
Gross Margin | 0.00% N/A | 0.00% N/A | N/A N/A | N/A N/A | |
Operating Margin | -891.07% +60.32% | -555.82% +163.90% | -210.62% -38.84% | -344.37% +149.49% | |
Return on Assets | -22.89% -20.57% | -28.81% +15.57% | -24.93% -2.64% | -25.61% +39.66% | |
Return on Equity | -25.78% -29.14% | -36.38% +9.56% | -33.21% +1.87% | -32.60% +20.93% | |
Revenue Growth | -16.70% -58.36% | -40.11% -159.12% | 67.84% +289.99% | -35.71% -131.32% | |
Current Ratio | 10.47 +39.05% | 7.53 +59.19% | 4.73 -19.54% | 5.88 +20.56% | |
Cash Ratio | 4.29 +141.77% | 1.77 +38.28% | 1.28 +33.86% | 0.96 +84.93% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow